NCT01159496View on ClinicalTrials.gov

Multiple Ascending Dose Study To Assess Safety, Tolerability And Pharmacokinetics Of PF-05212377 (SAM-760)

PHASE1CompletedINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Healthy

Interventions

DRUG

PF-05212377 (SAM-760)

Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg

DRUG

Placebo

Oral capsule, once daily for 14 days

Trial Locations (1)

92502

Pfizer Investigational Site, Rueil-Malmaison

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY